Crizotinib
As of the edition of 20 October 2026, Crizotinib is a small molecule: marketed, first approved in 2011 (US); acts on ALK, MET and ROS1; US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Xalkori
- First approved
- 26 August 2011 (US)
- Approvals on record
- 11 in 5 regions
- Holder of the most recent approval
- Pfizer; 3 holders in all
- Registered trials
- 105, 16 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Immune system; Digestive system; Heart and blood vessels
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product14 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 14 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Crizotinib.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 6 | 2 | 0 |
| Phase 1 | 36 | 28 | 1 | 7 |
| Phase 2 | 45 | 18 | 13 | 7 |
| Phase 3 | 7 | 3 | 3 | 0 |
| Phase 4 | 4 | 0 | 1 | 2 |
| All trials | 105 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator, Applicant and Lead sponsor of trials | 2011 to now |